Form 4: Director Paul Johnson Acquires Lifecore Biomedical Shares

Director Paul Harold Johnson acquired 25,907 shares of Lifecore Biomedical, Inc. common stock via restricted stock unit conversion.

Summary

• Director Paul Harold Johnson was granted 25,907 restricted stock units (RSUs).
• The RSUs convert to common stock on a 1-for-1 basis.
• Following this transaction, the director's total beneficial ownership in the company is 69,967 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation and equity alignment, which is neutral in nature.

Positives

• Increased equity alignment between the director and shareholders.

Negatives

• None identified.

Risks

• Vesting is subject to the earlier of June 4, 2027, or the 2027 annual meeting of stockholders, provided the date is at least 50 weeks from the grant date.

Future Outlook

The director's holdings will vest on the earlier of June 4, 2027, or the 2027 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices intended to align leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard compensation practices for publicly traded biomedical companies.

Stakeholder Impact

• Increased alignment of director interests with those of common shareholders.

Next Steps

• Vesting of the 25,907 restricted stock units on or after June 4, 2027.

Key Dates

Keywords

Lifecore Biomedical, LFCR, Insider Trading, Form 4, Director Ownership